个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Chang Xiujuan[1] * ; Li Yinying[1] * ; Sun Chao[2] * ; Li Xiaodong[3] * ; Du Wenjuan[4] ; Shang Qinghua[5] ; Song Laicheng[6] ; Long Qinghua[7] ; Li Qin[8] ; Liu Huabao[9] ; Wang Jing[10] ; Yu Zujiang[11] ; Li Jiang[12] ; Xiao Guangming[13] ; Li Li[14] ; Chen Liang[15] ; Tan Lin[16] ; Chen Yongping[17] ; Yang Yongping[1,2] ;
机构： [1]Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. [2]Chinese PLA Medical School, Beijing, 100853, China. [3]Department of Research for Clinical Medicine, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. [4]Discipline and Degree Division, the Graduate School of the PLA General Hospital, Beijing, 100853, China. [5]Center of Therapeutic Liver Disease, the 88th Hospital of Chinese PLA, Taian, 271000, Shandong Province, China. [6]Traditional Chinese Medicine Hospital of Taihe, Taihe, 400038, Anhui Province, China. [7]Department of Infection and Liver Disease, Yichun People's Hospital, Yichun, Jiangxi Province, China. [8]Fuzhou Infectious Diseases Hospital, Fuzhou, 350025, Fujian Province, China. [9]Traditional Chinese Medicine Hospital of Chongqing, Chongqing, 400038, China. [10]Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 610072, Sichuan Province, China. [11]Department of Infectious Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China. [12]Department of Infectious Diseases, Southwest Hospital, Army Military Medical University, Chongqing, 400038, China. [13]Guangzhou 8th People's Hospital, Guangzhou, 510060, Guangdong Province, China. [14]Department of Traditional Chinese Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. [15]Department of Hepatic Diseases, Shanghai Public Health Clinical Center, Shanghai, 201508, China. [16]Department of Liver Disease, Fuyang 2nd People's Hospital, Fuyang, 236015, Anhui Province, China. [17]Department of Infectious and Liver Diseases, Liver Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang Province, China.
出处：
DOI： 10.1007/s00535-023-01970-3
ISSN：

摘要：
Progressive hepatic fibrosis leads to hepatocellular carcinoma (HCC) and decompensated cirrhosis. The aim of this study was to identify the high-risk population for progressive hepatic fibrosis and the incidence of HCC and decompensated cirrhosis in chronic hepatitis B (CHB) patients with antiviral therapy.The data came from a multicenter, center-randomized, double-blind clinical trial that analyzed only patients in the ETV-treated arm. There was 156 hepatitis B e antigen (HBeAg)-positive and 135 HBeAg-negative patients in 14 institutions. The primary endpoint was fibrosis reversal on 72-week Entecavir (ETV) treatment. The 7-year cumulative incidence of HCC and decompensated cirrhosis were analyzed. Multivariate logistic and LASSO regression analyses were used to screen variables associated with fibrosis reversal.86/156 (55%) HBeAg-positive and 58/135 (43%) HBeAg-negative patients achieved fibrosis reversal on 72-week ETV treatment. Average age was 43 years, 203 (69.8%) was male, and 144 (49.5%) patients had cirrhosis. Age ≥ 40 years (OR: 0.46, 95% CI 0.23-0.93) and HBcrAg ≥ 8.23 log U/ml (OR: 2.72, 95% CI 1.33-5.54) in HBeAg-positive patients and HBV genotype C (OR: 0.44, 95% CI 0.21-0.97) in HBeAg-negative patients were independent factors of fibrosis reversal. It was confirmed in patients with cirrhosis. After 7-year ETV treatment, seven (4.5%) HBeAg-positive patients occurred HCC or decompensated cirrhosis, including four patients with age ≥ 40 years and six with HBcrAg 8.23log U/ml, while twelve (8.9%) HBeAg-negative patients occurred, including eleven with HBV genotype C.HBeAg-positive patients with a low HBcrAg level or old age, and HBeAg-negative patients with HBV genotype C tended to develop progressive hepatic fibrosis and had a high incidence of HCC and decompensated cirrhosis, even on ETV treatment.© 2023. Japanese Society of Gastroenterology.

基金：
Major Science and Technology Special Project of China (2018ZX10725-506) and Beijing Natural Science Foundation (7212101) for funding support.
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 2 区 胃肠肝病学
最新[2025]版：
大类 | 1 区 医学
小类 | 2 区 胃肠肝病学
JCR分区：
出版当年[2021]版：
Q2 GASTROENTEROLOGY & HEPATOLOGY
最新[2023]版：
Q1 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. [2]Chinese PLA Medical School, Beijing, 100853, China.
推荐引用方式(GB/T 7714)：
Chang Xiujuan,Li Yinying,Sun Chao,et al.High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy[J].JOURNAL OF GASTROENTEROLOGY.2023,58(5):481-493.doi:10.1007/s00535-023-01970-3.
APA：
Chang Xiujuan,Li Yinying,Sun Chao,Li Xiaodong,Du Wenjuan...&Yang Yongping.(2023).High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.JOURNAL OF GASTROENTEROLOGY,58,(5)
MLA：
Chang Xiujuan,et al."High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy".JOURNAL OF GASTROENTEROLOGY 58..5(2023):481-493

资源点击量：2022 今日访问量：0 总访问量：648 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号